A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3004-3004 ◽  
Author(s):  
G. Edelman ◽  
C. Bedell ◽  
G. Shapiro ◽  
S. S. Pandya ◽  
E. L. Kwak ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Escalation ◽  
Pi3k Inhibitor ◽  
Dose Escalation Study ◽  
Advanced Malignancies

A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3052-3052 ◽  
Author(s):  
D. D. Von Hoff ◽  
P. LoRusso ◽  
G. D. Demetri ◽  
G. J. Weiss ◽  
G. Shapiro ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Pi3k Inhibitor ◽  
Dose Escalation Study

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies

2006 ◽  
Vol 24 (5) ◽  
pp. 413-421 ◽  
Author(s):  
Hervé Ghesquières ◽  
Sandrine Faivre ◽  
Latifa Djafari ◽  
Patricia Pautier ◽  
Catherine Lhommé ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Escalation ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Dose Escalation Study ◽  
Advanced Malignancies

scholarly journals Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

2017 ◽  
Vol 7 (7) ◽  
pp. 704-715 ◽  
Author(s):  
Dejan Juric ◽  
Ian Krop ◽  
Ramesh K. Ramanathan ◽  
Timothy R. Wilson ◽  
Joseph A. Ware ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies

2008 ◽  
Vol 26 (4) ◽  
pp. 347-354 ◽  
Author(s):  
Priscila H. Goncalves ◽  
Francine High ◽  
Paul Juniewicz ◽  
Gareth Shackleton ◽  
Jing Li ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Escalation ◽  
Dose Escalation Study ◽  
Advanced Malignancies

scholarly journals Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147), a Pan‐Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors

2015 ◽  
Vol 20 (3) ◽  
pp. 245-246 ◽  
Author(s):  
Jean‐Charles Soria ◽  
Patricia LoRusso ◽  
Ratislav Bahleda ◽  
Joanne Lager ◽  
Li Liu ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Dose Escalation Study

scholarly journals Phase I, multicenter, dose‐escalation study of avadomide in adult Japanese patients with advanced malignancies

2020 ◽  
Vol 112 (1) ◽  
pp. 331-338
Author(s):  
Kiyohiko Hatake ◽  
Takaaki Chou ◽  
Toshihiko Doi ◽  
Yasuhito Terui ◽  
Harumi Kato ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Escalation ◽  
Japanese Patients ◽  
Dose Escalation Study ◽  
Advanced Malignancies
Sign in / Sign up

Export Citation Format

Share Document